title: Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports.
abstract: In vitro anticancer drug sensitivity tests have been performed for various types of cancers, and a relationship with clinical response has been observed. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) is a new in vitro anticancer drug sensitivity test by Yabushita et al., recently reported to be useful in ovarian cancer. CD-DST allows analysis of a small number of cells, compared to other anticancer drug sensitivity tests. Here, we report a successful analysis of anticancer drug sensitivity by CD-DST using cancerous ascites and pleural fluid samples from 2 patients with advanced ovarian cancer. To our knowledge, this is only the second report of the application of CD-DST in ovarian cancer, and our results suggest that CD-DST could be helpful in the selection of anticancer drugs for neoadjuvant chemotherapy in advanced ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Kawaguchi
authors.forename: Kouji
authors.initials: K
authors.lastname: Banno
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Susumu
authors.forename: Megumi
authors.initials: M
authors.lastname: Yanokura
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: Nobumaru
authors.initials: N
authors.lastname: Hirao
authors.forename: Katsumi
authors.initials: K
authors.lastname: Tsukazaki
authors.forename: Shiro
authors.initials: S
authors.lastname: Nozawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001201:Ascites / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D016066:Pleural Effusion, Malignant / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D000077146:Irinotecan; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin